FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. (Q49132819)
Jump to navigation
Jump to search
scientific article published on 23 March 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. |
scientific article published on 23 March 2015 |
Statements
1 reference
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. (English)
1 reference
Hyon-Zu Lee
1 reference
Virginia E Kwitkowski
1 reference
Pedro L Del Valle
1 reference
M Stacey Ricci
1 reference
Haleh Saber
1 reference
Bahru A Habtemariam
1 reference
Julie Bullock
1 reference
Erik Bloomquist
1 reference
Yuan Li Shen
1 reference
Xiao-Hong Chen
1 reference
Janice Brown
1 reference
Nitin Mehrotra
1 reference
Sarah Dorff
1 reference
Rosane Charlab
1 reference
Robert C Kane
1 reference
Edvardas Kaminskas
1 reference
Robert Justice
1 reference
Ann T Farrell
1 reference
Richard Pazdur
1 reference
23 March 2015
1 reference
1 reference
21
1 reference
12
1 reference
2666-2670
1 reference
Identifiers
1 reference
1 reference